Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) is expected to be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $1.72 million for the quarter.
Lineage Cell Therapeutics Price Performance
NYSEAMERICAN:LCTX traded down $0.01 on Friday, reaching $0.49. The stock had a trading volume of 443,271 shares, compared to its average volume of 1,324,073. The company has a market cap of $108.16 million, a price-to-earnings ratio of -4.09 and a beta of 1.21. Lineage Cell Therapeutics has a 12-month low of $0.37 and a 12-month high of $1.40. The firm's fifty day moving average is $0.49 and its two-hundred day moving average is $0.64.
Analyst Ratings Changes
Several research analysts have weighed in on LCTX shares. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. D. Boral Capital reiterated a "buy" rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. B. Riley decreased their price target on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating on the stock in a research note on Friday, March 14th. Finally, Maxim Group cut their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a "buy" rating on the stock in a report on Friday, January 10th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $4.20.
Check Out Our Latest Research Report on LCTX
Lineage Cell Therapeutics Company Profile
(
Get Free Report)
Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
Read More
Before you consider Lineage Cell Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.
While Lineage Cell Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
